Skip to content

Similar metrics at other companies

Vertex Pharmaceuticals logo
VRTXJOURNAVX — Product revenues, net
$29M+2,131%
XER
XERSProduct revenue, net — Product revenue, net
$82.45M+42.6%
Nuvation Bio logo
NUVBJP — Revenue
$652K+256%
Bristol-Myers Squibb logo
BMYGrowth Portfolio — Total Revenues
$6.23B+11.9%
Crinetics Pharmaceuticals logo
CRNXProduct revenue, net — Total Revenue
$10.31M
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.15B+20.4%
Enterprise value$869.67M+2.5%
P/E15.4×-6.4×
P/S1.5×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.

The official record: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s jornay pm — 2030.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s jornay PM — 2030?
Collegium Pharmaceutical, Inc. (COLL) reported jornay PM — 2030 of $83.83M in Q4 2025.
What does jornay PM — 2030 mean?
This metric tracks the financial performance of a specific pharmaceutical asset as it approaches its long-term strategic horizon. It captures the net revenue generation and amortization profile of the product, reflecting its contribution to the company's multi-year growth strategy. This data point is essential for evaluating the product's lifecycle management and its role in the company's future earnings capacity.